NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches, today announced promising initial data from the Phase 2 CONVERGE study evaluating its lead candidate, JNJ-1900 (NBTXR3), in patients with stage 3 inoperable non-small cell lung cancer (NSCLC).
The findings were presented during the 2026 European Lung Cancer Conference (ELCC) in a poster session on March 30.
The CONVERGE study is a randomized Phase 2 trial investigating JNJ-1900—a first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles—combined with standard-of-care chemoradiation followed by consolidation immunotherapy.
The reported data from the first seven evaluable patients showed an objective response rate (ORR) of 71.4% and a disease control rate (DCR) of 100%.
These initial efficacy signals compare favorably to an estimated historical benchmark ORR of 45%–50% for patients receiving standard concurrent chemoradiotherapy.
Safety remains a primary focus for the intratumorally injected nanoparticle, and the initial report indicates an acceptable safety profile.
There were no serious treatment-emergent adverse events (TEAEs) related to JNJ-1900 reported in this cohort, and the administration procedure did not interfere with patients' ability to continue their planned course of radiotherapy or systemic therapy.
While the lung cancer data is still in its early stages, the high response rate and lack of new safety signals support the continued expansion of the CONVERGE trial as Nanobiotix and its partners move toward a more robust data set in late 2026 and 2027.